Deficiency of protein G s (Gs; OMIM no.103580), the stimulatory regulator of adenylyl cyclase, is associated with resistance to PTH and other hormones, sc calcifications, short stature, and skeletal defects (Albright's hereditary osteodystrophy). It is caused by heterozygous loss of function mutations in GNAS1, the gene encoding the ␣-subunit of G s . Obesity is a classical feature of patients with G s deficiency, but the mechanism leading to fat accumulation has not been elucidated. We measured glycerol flux, using a nonradioactive tracer dilution approach, to analyze the lipolytic response to epinephrine in 6 patients with G s deficiency and PTH resistance and compared it to six age-matched normal controls and nine massively obese children. Basal glycerol production was reduced by 50%, and lipolytic response to epinephrine was reduced by 67%, in G s -deficient children, as compared with controls. The degree of impairment of lipolysis was similar in G s -deficient children who were only moderately overweight and in morbidly obese children. These findings extend the spectrum of hormonal resistance in G s deficiency. Besides ␤-adrenergic receptors, G s protein itself should be examined as a possible step involved in the decreased lipolysis observed in common obesity. (J Clin Endocrinol Metab 84:4127-4131, 1999) 
D
EFICIENCY of protein G s (G s ), the stimulatory regulator of adenylyl cyclase, is associated with heterogeneous clinical manifestations. Although resistance to PTH was the first reported feature, further studies revealed resistance to other hormones (TSH, gonadotropins, glucagon), as well as additional manifestations: sc calcifications, Albright's hereditary osteodystrophy, hearing impairment, and some degree of mental retardation (OMIM no.103580; for review, see Refs. 1 and 2). Genetic analysis revealed heterozygous loss of function mutation in GNAS1, the gene encoding the ␣-subunit of G s (3) (4) (5) (6) (7) (8) , transmitted as an autosomal dominant trait with incomplete penetrance.
A striking feature of the disease is the variability of the clinical and biochemical abnormalities, not explained by the various molecular defects of the protein. Also of interest is the persistence of normal distal responses to some of the hormones signaling through G s (such as vasopressin and glucagon). Obesity is a classical feature of patients with G s deficiency (1) , but the mechanism leading to fat accumulation has not been elucidated (9 -11) . Mobilization of fat stores occurs in adipose tissue through the hydrolysis of triglycerides into glycerol and fatty acids (lipolysis). While insulin has a powerful antilipolytic effect, catecholamines are the major hormones stimulating triglyceride hydrolysis in man (12) . The effects of catecholamines are initiated by binding to lipolytic ␤-adrenoreceptors and antilipolytic ␣ 2 -adrenoreceptors in white adipose tissue (12) . Activated adrenoreceptors regulate adenylate cyclase activity, cAMP production, and protein kinase A, resulting in phosphorylation and activation of hormone-sensitive lipase, which breaks down triglycerides to glycerol and free fatty acids (FFA), via di-and monoacylglycerol intermediates (13) . In a recent in vivo study of obese children in the dynamic phase of obesity, we found that the lipolytic effect of catecholamines was markedly decreased, supporting a role for catecholamine resistance in the increased fat accumulation (14) . A resistance of lipolysis to catecholamines was also found in abdominal sc fat cells of normal-weight first-degree relatives of obese adults (15) , suggesting that this alteration could be a primary mechanism.
Because obesity is frequently associated with G s deficiency and G s is part of the pathway transducing the lipolytic signal through ␤-adrenergic receptors, we tested whether epinephrine resistance was part of the spectrum of hormonal resistance in patients with G s deficiency. We found that patients with G s deficiency are resistant to the lipolytic actions of epinephrine.
Subjects and Methods

Subjects (Table 1)
Six children (four boys, two girls), with G s deficiency were studied. Two of them (one boy, one girl) were sibs. The initial manifestations of G s deficiency was hypocalcemia (5/6) or short stature and dysmorphic features (1/6). All patients had clinical features of Albright's hereditary osteodystrophy (in particular, short fourth and fifth metacarpals) and decreased erythrocyte G s activity (63 Ϯ 3%; range, 50 -73%). All six patients had PTH resistance and were treated with vitamin D at the time of the study; 5/6 had TSH resistance and were treated with l-T 4 . They were compared to six normal children (four boys, two girls) and nine obese children (four boys, five girls) recruited according to approval of the institutional ethical committee, as described in (14) . Because the results in obese children have already been published (14) , only the baseline data and glycerol flux data will be presented here, since they were studied with the same methodology as were Gs-deficient children.
Procedural methods
All subjects consumed an isocaloric standard diet 72 hr before the study. Studies were performed at 0800 h, following an overnight 12-h fast. After collection of a baseline sample, infusion of the [1,1,2,3,3-2 H 5 ] glycerol tracer (ISOTEC, Miamisburg, OH) began with a priming dose, followed by continuous infusion at a constant rate of 0.063 Ϯ 0.003 mol ϫ kg Ϫ1 ϫ min Ϫ1 for 3 hr. In controls, insulin was infused at a minimal rate of 0.20 mU/kg ϫ min, starting with glycerol infusion, to reach a plasma level of insulin comparable with G s -deficient children, whereas plasma glucose was maintained nearly constant (16, 17) . Epinephrine infusion started at 60 min, at a rate of 0.75 g/min for 60 min, then at 1.5 g/min for another 60-min period. Epinephrine doses were similar for G s -deficient and lean children and were calculated to induce lipolysis while minimally stimulating the cardiovascular system, according to previous studies in adult men (18 -20) . Blood samples (for the measurement of plasma glycerol concentration, [ 2 H 5 ] enrichment, plasma FFA, leptin, epinephrine, norepinephrine, and insulin) were taken at baseline and at 10-min intervals during the last 30 min of the two study periods.
Analytical procedures and calculations
Details on the assays for plasma FFA, insulin, epinephrine, norepinephrine, and glycerol [ 2 H 5 ] enrichment have been reported (14) . Ra, the rate of appearance of endogenous glycerol in plasma, and Rd (the rate of its disposal) were quantified in basal conditions and during the epinephrine infusion. Because individual glycerol concentrations and enrichments varied within less than 10% of mean value during the last 20 min of each 60-min study period, we used a steady-state dilution equation to calculate glycerol turnover (see Ref. 24) . Ra and Rd were equal and expressed in mol/min to figure whole-body glycerol fluxes. Glycerol release was normalized to fat mass, as recommended (21, 22 ). Erythrocyte G s activity was measured as described (23) and was expressed as percent of an internal standard (normal Ͼ 83%).
Statistical analysis
Data are presented as mean Ϯ se. Statistical comparison between groups was performed with a two-tailed Student's t test for unpaired data. The relationship between variables was evaluated using simple linear regression analysis. To compare the response of each variable (glycerol flux, plasma FFA, heart rate, or plasma glucose) to epinephrine between subjects, we used the standard two stages (STS) (NIH) method described by Feldman (24) . For each individual (i), we calculated the slopes of the regression lines (variable) ϭ ␤i⅐(epinephrine) ϩ ␣i. The slope of such a regression line, ␤i, represents the proportional increase of the variable, in response to a unit change in epinephrine. The means Ϯ se of these slopes were calculated and compared between G s -deficient and control children, by unpaired t test.
Results
Plasma substrates and hormones
Basal state. Basal plasma glycerol, glucose, and FFA concentrations were comparable in G s -deficient and control children (Table 2 , data not shown for obese children). In G sdeficient children, plasma epinephrine was 197 Ϯ 48 pg/mL vs. 150 Ϯ 22 pg/mL in normal children (not significant, NS) and 299 Ϯ 62 in obese children (P Ͻ 0.025 vs. lean children). Plasma norepinephrine was 412 Ϯ 107 pg/mL in G s -deficient patients and 1507 Ϯ 256 pg/mL in normal children (P Ͻ 0.005). Plasma leptin and insulin were higher in obese and G s -deficient children, as expected from their increased body mass index (BMI).
Epinephrine infusion. Plasma substrate concentrations during epinephrine infusion are shown on Table 2 . The increase of plasma FFA concentration was slightly (but non significantly) reduced in G s -deficient children, despite the greater elevation of plasma epinephrine. The mean slope of the individual regression equations (␤, in mol⅐mL⅐l Ϫ1 ⅐pg
Ϫ1
) was 0.16 Ϯ 0.08 in G s -deficient and 0.40 Ϯ 0.08 in control children (P ϭ 0.06), indicating that in response to epinephrine infusion, FFA release tended to be decreased in G s -deficient children. The relative increase of plasma FFA in G s -deficient patients was 172% and 211% of basal value after step 1 and step 2 vs. 172% and 242% in control children. The increment of plasma glycerol in response to epinephrine was similar in both groups. The mean slope of the individual regression equations (␤, in mol/min or mol⅐min Ϫ1 ) was 0.23 Ϯ 0.03 in G s -deficient and 0.26 Ϯ 0.07 in control children.
Glycerol production (Fig. 1) Basal. Basal glycerol production was lower in G s -deficient (146 Ϯ 18 mol/min or mol⅐min Ϫ1 and obese (176 Ϯ 25 mol/min or mol⅐min Ϫ1 ) than in control children (294 Ϯ 35 mole/min or mol⅐min Ϫ1 ; respectively, P Ͻ 0.005 and P Ͻ 0.02, Fig. 1A) . This difference persisted after normalization to adipose tissue mass, revealing that glycerol release per unit fat mass was 49% lower in G s -deficient (9.3 Ϯ 0.8 mol⅐min Ϫ1 ⅐kg fat mass Ϫ1 ) and 65% lower in obese (6.3 Ϯ 1.1 mol⅐min Ϫ1⅐ ⅐kg fat mass Ϫ1 ) than in control children (18.2 Ϯ 1.4 mol⅐min Ϫ1 ⅐kg fat mass Ϫ1 , P Ͻ 0.0005 vs. both groups, Fig. 1B ).
Epinephrine infusion. During steps 1 and 2 of epinephrine infusion, glycerol production increased to 500 Ϯ 74 and 713 Ϯ 94 mol/min or mol⅐min Ϫ1 in control children and to 212 Ϯ 19 and 254 Ϯ 36 mol/min or mol⅐min Ϫ1 in G s -deficient children (Fig. 1A) . The mean ␤-slope of the individual formulas (glycerol flux ϭ ␤i [Epi] ϩ ␣i) was 0.47 Ϯ 0.17
in G s -deficient, 0.39 Ϯ 0.13 mol⅐ml⅐min Ϫ1 ⅐pg Ϫ1 in obese, and 1.43 Ϯ 0.27 in control children (P Ͻ 0.02, Gs-deficient vs. lean; P Ͻ 0.002, obese vs. lean; NS, Gs-deficient vs. obese). The relative increase of glycerol production in G s -deficient patients was only 152% and 182% of basal value after step 1 and step 2 vs. 171% and 266% in control children (Fig. 1A) . These results indicate a markedly decreased glycerol production in response to epinephrine in G s -deficient children. For a similar increase of plasma epinephrine, the response of glycerol production was 67% lower in G s -deficient children and 73% lower in obese children, as compared with lean children. The respective slopes of glycerol flux and plasma FFA, in response to epinephrine, were closely correlated (r ϭ 0.67, P Ͻ 0.02, both groups combined). In contrast, no correlation was found between the slopes of glycerol flux and plasma glycerol in response to epinephrine.
Heart rate (Table 2)
The resting heart rate was significantly higher in G s -deficient patients (68 Ϯ 4 vs. 58 Ϯ 2, P Ͻ 0.05). During epinephrine infusion, the relative increase of heart rate was 115% and 132% of basal value in control children, consistent with the expected effects of small doses of epinephrine (18 -20) . In G s -deficient patients, the increase was only 105% and 112%. The mean ␤-slope of the individual regression equations (heart rate ϭ ␤i [Epi] ϩ ␣i) was 0.035 Ϯ 0.006 in G sdeficient and 0.063 Ϯ 0.011 in control children (P ϭ 0.051). Therefore, the chronotropic response to epinephrine seems to be slightly (or not) affected by G s deficiency.
Discussion
The present data indicate that, in G s -deficient children, the mobilization of triglyceride stores, per unit of fat mass, is decreased by approximately 50% in the basal state. Elevation of epinephrine levels within the physiological range (488 Ϯ 60 and 397 Ϯ 42 pg/mL in G s -deficient and control children, respectively) resulted in a markedly increased glycerol production in control children, contrasting with the resistance observed in G s -deficient children. Although we could not perform a complete dose-response curve of glycerol release to serum epinephrine in vivo, our results suggest that both the maximal response and the ED50 were diminished in the G s -deficient children.
Our patients were mildly overweight (123 Ϯ 5% of ideal body weight; range, 107-141%) and were compared to a group of lean children (similar fat mass, lower BMI) and to a group of obese children with much higher BMI and fat mass. Under epinephrine stimulation, the slope of response of glycerol production was similarly reduced in obese (Ϫ73% vs. controls) and in G s -deficient (Ϫ67% vs. controls) patients, and the dose response curve of these two groups on Fig. 1A looks very similar. This indicates that, in obese and Gsdeficient individuals, the capacity of adipose tissue to respond to a similar increment of epinephrine is markedly decreased, even though most of our Gs-deficient patients do not reach the commonly accepted threshold used to define obesity. The expression of data per kg of fat mass shows that fluxes are further reduced in massively obese children but that the slope is still similar in both pathological groups (Fig.  1B) . Previous studies of adrenergic response in patients with pseudohypoparathyroidism (PHP) (9, 10) have investigated heterogeneous groups of adult patients with decreased or normal erythrocyte G s activity, i.e. patients that would now be classified, respectively, as PHP Ia or Ib (2) . These studies have concluded at a blunted cAMP response and a normal FFA response to isoproterenol. Similarly, a blunted stimulatory response of adenylate cyclase was observed in the plasma membranes of adipocytes from four patients with PHP Ia and decreased erythrocyte G s activity (11) . Our studies, in a more homogeneous group of patients with G s deficiency and PHP Ia, indicate that the end organ response to adrenergic stimulation is markedly decreased and might contribute to the obesity frequently observed in these patients. However, our patients were only mildly overweight, suggesting that, at least in children, regulatory pathways limit the expansion of body fat mass. For instance, insulin sensitivity at the adipose tissue level could counterbalance the detrimental effect of epinephrine resistance, a hypothesis that can be tested (17) . The clinical picture of G s deficiency is extremely variable, even in individuals of the same family, known to harbor the same mutation. Part of this variability could be caused by imprinting of the GNAS1 gene (25) , but no direct evidence has been obtained in the human so far (26, 27) . In the mouse, tissue-specific imprinting of Gnas, the mouse homolog of GNAS1, has been demonstrated in knockout mice with a null allele of Gnas (28) . In addition to paternal imprinting in the renal cortex (the site of PTH action), but not in the renal medulla, Gnas was paternally imprinted in the brown and white adipose tissue. Heterozygous mice, inheriting the null allele from the mother, accumulated fat and became obese in early adulthood. Oppositely, mice inheriting the null allele from their father were leaner than normal, a situation dissimilar to the humans, where patients with paternal inheritance of Albright's hereditary osteodystrophy tend to also be obese. Further studies should address the question of adipocyte response to epinephrine in vivo and in vitro in individuals with Albright's hereditary osteodystrophy and normal PTH response (pseudo-PHP).
Decreased lipolytic activity has been implicated in common obesity, both in adults and in children. However, the mechanisms leading to a decreased activity of the key regulatory enzyme, hormone-sensitive lipase are not known (29) . Studies in abdominal sc fat cells of relatives of obese adults suggest that this impairment lies downstream of cAMP production (15) . Other studies point towards a decreased function of ␤-adrenergic receptors in common obesity. The level of expression of ␤ 2 receptors (30), as well as molecular variants of the ␤ 2 (31) and ␤ 3 receptors (32-36), have been discussed as possible mechanisms associated with obesity. Both ␤ 1 and ␤ 2 receptors are readily detectable on white adipose tissue in humans, whereas the expression of the ␤ 3 receptor is low, detectable only by reverse transcriptase PCR (37, 38) . The respective roles of these three receptors in epinephrine-induced lipolysis are still debated. Recent studies, using selective ␤ 3 -adrenergic receptor agonists in primate and human white adipose tissue, suggest that ␤ 3 receptors might be major mediators of the lipolytic action of epinephrine (39) . In our patients, G s deficiency, a step that has not been considered in common obesity, is expected to reduce signal transduction from all types of ␤-adrenergic receptors and could phenocopy other defects encountered in more common forms of obesity. In addition, it is conceivable that decreased G s activity or mutations in GNAS1 could be implicated in common obesity, in the absence of the characteristic multihormonal resistance observed in PHP. In vitro data also support the fact that quantitative variations of G s alter the efficacy of signal transduction to adenylyl cyclase (40, 41) .
In conclusion, the lipolytic response to epinephrine is markedly decreased in patients with G s deficiency and PTH resistance, extending the spectrum of hormonal resistance in G s deficiency. Our findings also point out regulatory mechanisms preventing the massive accumulation of fat in these patients, at least during childhood. Besides ␤-adrenergic receptors, G s protein itself should be examined as a possible step involved in the decreased lipolysis observed in common obesity.
